# Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

> **NCT06324357** · PHASE1,PHASE2 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 768 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Metastatic Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma
- Colorectal Cancer

## Interventions

- **DRUG:** Zongertinib
- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Trastuzumab emtansine
- **DRUG:** Trastuzumab
- **DRUG:** Capecitabine
- **DRUG:** mFOLFOX6
- **DRUG:** zanidatamab

## Key facts

- **NCT ID:** NCT06324357
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-03
- **Primary completion:** 2029-01-08
- **Final completion:** 2029-01-08
- **Target enrollment:** 768 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06324357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06324357, "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06324357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*